154 related articles for article (PubMed ID: 38603529)
1. Prevention and treatment of hypertensive left ventricular hypertrophy.
Tatavarthy M; Stathopoulos J; Oktay AA
Curr Opin Cardiol; 2024 Jul; 39(4):251-258. PubMed ID: 38603529
[TBL] [Abstract][Full Text] [Related]
2. The importance of left ventricular hypertrophy in human hypertension.
Kahan T
J Hypertens Suppl; 1998 Sep; 16(7):S23-9. PubMed ID: 9855028
[TBL] [Abstract][Full Text] [Related]
3. Left Ventricular Hypertrophy in Hypertensive Athletes can be Reduced by Antihypertensive Medication Despite Continuing Intense Aerobic Exercise.
Ketelhut S; Franz IW; Ketelhut RG
High Blood Press Cardiovasc Prev; 2018 Dec; 25(4):385-390. PubMed ID: 30341642
[TBL] [Abstract][Full Text] [Related]
4. Left ventricular hypertrophy and hypertension.
Yildiz M; Oktay AA; Stewart MH; Milani RV; Ventura HO; Lavie CJ
Prog Cardiovasc Dis; 2020; 63(1):10-21. PubMed ID: 31759953
[TBL] [Abstract][Full Text] [Related]
5. Anti-hypertensive drugs and left ventricular hypertrophy: a clinical update.
Milan A; Caserta MA; Avenatti E; Abram S; Veglio F
Intern Emerg Med; 2010 Dec; 5(6):469-79. PubMed ID: 20480263
[TBL] [Abstract][Full Text] [Related]
6. Regression of electrocardiographic left ventricular hypertrophy or strain is associated with lower incidence of cardiovascular morbidity and mortality in hypertensive patients independent of blood pressure reduction - A LIFE review.
Bang CN; Devereux RB; Okin PM
J Electrocardiol; 2014; 47(5):630-5. PubMed ID: 25052475
[TBL] [Abstract][Full Text] [Related]
7. Left ventricular hypertrophy and clinical outcomes in hypertensive patients.
Ruilope LM; Schmieder RE
Am J Hypertens; 2008 May; 21(5):500-8. PubMed ID: 18437140
[TBL] [Abstract][Full Text] [Related]
8. Effects of antihypertensive agents on the left ventricle: clinical implications.
Díez J; González A; López B; Ravassa S; Fortuño MA
Am J Cardiovasc Drugs; 2001; 1(4):263-79. PubMed ID: 14728026
[TBL] [Abstract][Full Text] [Related]
9. Regression of left ventricular hypertrophy in hypertension--does it reduce cardiovascular risk?
Braz Nogueira J
Rev Port Cardiol; 2005; 24(7-8):1007-13. PubMed ID: 16240686
[TBL] [Abstract][Full Text] [Related]
10. Regression of echocardiographic left ventricular hypertrophy after 2 years of therapy reduces cardiovascular risk in patients with essential hypertension.
Pierdomenico SD; Lapenna D; Cuccurullo F
Am J Hypertens; 2008 Apr; 21(4):464-70. PubMed ID: 18369364
[TBL] [Abstract][Full Text] [Related]
11. Angiotensin converting enzyme inhibition and dihydropyridine calcium channel blockade in the treatment of left ventricular hypertrophy in arterial hypertension.
Palmieri V; Devereux RB
Minerva Cardioangiol; 2002 Jun; 50(3):169-74. PubMed ID: 12107398
[TBL] [Abstract][Full Text] [Related]
12. Current Perspectives on Left Ventricular Geometry in Systemic Hypertension.
Oktay AA; Lavie CJ; Milani RV; Ventura HO; Gilliland YE; Shah S; Cash ME
Prog Cardiovasc Dis; 2016; 59(3):235-246. PubMed ID: 27614172
[TBL] [Abstract][Full Text] [Related]
13. Effects of irbesartan on phenotypic alterations in monocytes and the inflammatory status of hypertensive patients with left ventricular hypertrophy.
Zhang J; Yang L; Ding Y
BMC Cardiovasc Disord; 2021 Apr; 21(1):194. PubMed ID: 33879070
[TBL] [Abstract][Full Text] [Related]
14. Left ventricular hypertrophy: how to influence an important risk factor in hypertension.
Agabiti-Rosei E; Muiesan ML
J Hypertens Suppl; 1998 Jan; 16(1):S53-8. PubMed ID: 9534098
[TBL] [Abstract][Full Text] [Related]
15. Impact of Chamber Dilatation on the Prognostic Value of Left Ventricular Geometry in Hypertension.
Verdecchia P; Angeli F; Mazzotta G; Bartolini C; Garofoli M; Aita A; Poltronieri C; Pinzagli MG; Valecchi F; Martone S; Ramundo E; Turturiello D; Reboldi G
J Am Heart Assoc; 2017 May; 6(6):. PubMed ID: 28539381
[TBL] [Abstract][Full Text] [Related]
16. Regression of hypertensive left ventricular hypertrophy by losartan compared with atenolol: the Losartan Intervention for Endpoint Reduction in Hypertension (LIFE) trial.
Devereux RB; Dahlöf B; Gerdts E; Boman K; Nieminen MS; Papademetriou V; Rokkedal J; Harris KE; Edelman JM; Wachtell K
Circulation; 2004 Sep; 110(11):1456-62. PubMed ID: 15326072
[TBL] [Abstract][Full Text] [Related]
17. Early target organ damage and its reversibility: the heart.
Rosei EA; Muiesan ML
Clin Exp Hypertens; 2004; 26(7-8):673-87. PubMed ID: 15702622
[TBL] [Abstract][Full Text] [Related]
18. Progressive hypertrophy regression with sustained pressure reduction in hypertension: the Losartan Intervention For Endpoint Reduction study.
Devereux RB; Palmieri V; Liu JE; Wachtell K; Bella JN; Boman K; Gerdts E; Nieminen MS; Papademetriou V; Dahlöf B
J Hypertens; 2002 Jul; 20(7):1445-50. PubMed ID: 12131543
[TBL] [Abstract][Full Text] [Related]
19. Echocardiographic left ventricular geometry in hypertensive patients with electrocardiographic left ventricular hypertrophy: The LIFE Study.
Devereux RB; Bella J; Boman K; Gerdts E; Nieminen MS; Rokkedal J; Papademetriou V; Wachtell K; Wright J; Paranicas M; Okin PM; Roman MJ; Smith G; Dahlöf B
Blood Press; 2001; 10(2):74-82. PubMed ID: 11467763
[TBL] [Abstract][Full Text] [Related]
20. Optimal antihypertensive therapy for prevention and treatment of left ventricular hypertrophy.
Liebson PR; Serry RD
Curr Hypertens Rep; 2000 Jun; 2(3):260-70. PubMed ID: 10981159
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
